乳腺癌保乳手术切缘状态与生存结局:前瞻性注册的系统综述与Meta分析
该前瞻性注册的系统综述与Meta分析纳入68项研究、112,140例早期浸润性乳腺癌保乳手术患者,评估切缘状态与远处复发及局部复发的关系。结果显示切缘阳性(肿瘤累及墨水)和切缘近(距肿瘤<2 mm)均与远处复发和局部复发风险升高相关;作者建议外科医生应争取达到至少1 mm的清晰切缘,并认为国际指南应据此修订。
要点
- 切缘阳性(肿瘤累及墨水)患者远处复发率25.4%(95%CI 14.5%–40.6%),切缘阴性患者为7.4%(95%CI 3.9%–13.6%)。
- 与切缘阴性相比,切缘阳性者远处复发风险升高(HR 2.10,95%CI 1.65–2.69,P<0.001)。
- 作者建议外科医生应争取达到至少1 mm的清晰切缘,并认为国际指南应据此修订。
核心结论
- 早期浸润性乳腺癌保乳术后切缘阳性或切缘近与远处复发和局部复发风险升高相关。
- 作者建议外科医生应争取达到至少1 mm的清晰切缘,并认为国际指南应据此修订。
研究设计与样本
- 前瞻性注册的系统综述与Meta分析,检索Medline(PubMed)、Embase和Proquest数据库,并向研究作者索取未发表数据。
- 纳入1980年1月1日至2021年12月31日发表的68项研究,共112,140例乳腺癌患者。
- 纳入标准为接受保乳手术的I–III期乳腺癌患者、可估计与切缘状态相关结局、随访至少60个月;排除仅导管原位癌、接受新辅助化疗或乳房切除术的患者。
- 切缘分类为肿瘤累及墨水(阳性)、切缘近(无肿瘤累及墨水但<2 mm)和切缘阴性(≥2 mm)。
主要发现
- 全部研究中,9.4%(95%CI 6.8%–12.8%)患者切缘阳性(肿瘤累及墨水),17.8%(95%CI 13.0%–23.9%)为切缘阳性或切缘近。
- 远处复发率在切缘阳性患者为25.4%(95%CI 14.5%–40.6%),在切缘阳性或切缘近患者为8.4%(95%CI 4.4%–15.5%),在切缘阴性患者为7.4%(95%CI 3.9%–13.6%)。
- 与切缘阴性相比,切缘阳性与远处复发风险升高相关(HR 2.10,95%CI 1.65–2.69,P<0.001),与局部复发风险升高相关(HR 1.98,95%CI 1.66–2.36,P<0.001)。
- 调整辅助化疗和放疗后,与切缘阴性相比,切缘近与远处复发风险升高相关(HR 1.38,95%CI 1.13–1.69,P<0.001),与局部复发风险升高相关(HR 2.09,95%CI 1.39–3.13,P<0.001)。
- 2010年以来发表的5项研究中,与切缘阴性相比,切缘阳性与远处复发风险升高相关(HR 2.41,95%CI 1.81–3.21,P<0.001),切缘阳性或切缘近亦与远处复发风险升高相关(HR 1.44,95%CI 1.22–1.71,P<0.001)。
关键数值与推荐
- 切缘阳性定义为肿瘤累及墨水(involved)。
- 切缘近定义为无肿瘤累及墨水但<2 mm。
- 切缘阴性定义为≥2 mm。
- 作者建议外科医生应争取达到至少1 mm的清晰切缘。
临床怎么用
- 作者建议外科医生在早期浸润性乳腺癌保乳手术中应争取达到至少1 mm的清晰切缘。
- 作者认为基于当前证据,国际指南应进行修订。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if margin involvement is associated with distant recurrence and to determine the required margin to minimise both local recurrence and distant recurrence in early stage invasive breast cancer. DESIGN: Prospectively registered systematic review and meta-analysis of literature. DATA SOURCES: Medline (PubMed), Embase, and Proquest online databases. Unpublished data were sought from study authors. ELIGIBILITY CRITERIA: Eligible studies reported on patients undergoing breast conserving surgery (for stages I-III breast cancer), allowed an estimation of outcomes in relation to margin status, and followed up patients for a minimum of 60 months. Patients with ductal carcinoma in situ only or treated with neoadjuvant chemotherapy or by mastectomy were excluded. Where applicable, margins were categorised as tumour on ink (involved), close margins (no tumour on ink but <2 mm), and negative margins (≥2 mm). RESULTS: 68 studies from 1 January 1980 to 31 December 2021, comprising 112 140 patients with breast cancer, were included. Across all studies, 9.4% (95% confidence interval 6.8% to 12.8%) of patients had involved (tumour on ink) margins and 17.8% (13.0% to 23.9%) had tumour on ink or a close margin. The rate of distant recurrence was 25.4% (14.5% to 40.6%) in patients with tumour on ink, 8.4% (4.4% to 15.5%) in patients with tumour on ink or close, and 7.4% (3.9% to 13.6%) in patients with negative margins. Compared with negative margins, tumour on ink margins were associated with increased distant recurrence (hazard ratio 2.10, 95% confidence interval 1.65 to 2.69, P<0.001) and local recurrence (1.98, 1.66 to 2.36, P<0.001). Close margins were associated with increased distant recurrence (1.38, 1.13 to 1.69, P<0.001) and local recurrence (2.09, 1.39 to 3.13, P<0.001) compared with negative margins, after adjusting for receipt of adjuvant chemotherapy and radiotherapy. In five studies published since 2010, tumour on ink margins were associated with increased distant recurrence (2.41, 1.81 to 3.21, P<0.001) as were tumour on ink and close margins (1.44, 1.22 to 1.71, P<0.001) compared with negative margins. CONCLUSIONS: Involved or close pathological margins after breast conserving surgery for early stage, invasive breast cancer are associated with increased distant recurrence and local recurrence. Surgeons should aim to achieve a minimum clear margin of at least 1 mm. On the basis of current evidence, international guidelines should be revised. SYSTEMATIC REVIEW REGISTRATION: CRD42021232115.
引用
- Bundred JR, Michael S, Stuart B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022. PMID: 36130770. doi:10.1136/bmj-2022-070346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。